Over six months of treatment, about twice as many people in the placebo group developed MS, compared
with those who took
minocycline. In absolute numbers, 61 per cent of the 70 participants in the placebo group developed MS, compared with 33 per cent of the 72 people taking the acne drug.
“(Minocycline) decreases the likelihood of getting MS in that six-month period,” said study author V. Wee Yong, who’s also a professor in the university’s Department of Clinical Neurosciences.